Neoplasm-induced pain

Neurobiology of Disease

Volumn , Issue , 2007, Pages 1007-1020

  Mercadante, Sebastiano ^a  

^a LA MADDALENA CANCER CENTER   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77649192068     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012088592-3/50094-3     Document Type: Chapter

References (22)

1. Cleeland C.S., Gonin R., Hatfield A.K., Edmonson J.H., Blum R.H., Stewart J.A., Pandya K.J. Pain and its treatment in outpatients with metastatic cancer. N. Engl. J. Med. 1994, 330:592-596.
2. Bruera E., Kim H.N. Cancer pain. JAMA 2003, 290:2476-2479.
3. Portenoy R.K., Conn M. Cancer pain syndromes. Cancer Pain, Assessment and Management 2003, 38-50. Cambridge University Press, London. E. Bruera, R.K. Portenoy (Eds.).
4. Besson J.M. The neurobiology of pain. Lancet 1999, 353:1610-1615.
5. Coderre T.J., Katz J., Vaccarino A.L., Melzack R. Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence. Pain 1993, 52:259-285.
6. Cervero F., Laird J.M.A. Visceral pain. Lancet 1999, 353:2145-2148.
7. Mao J., Price D., Mayer D.J. Experimental mononeu-ropathy reduces the antinociceptive effects of morphine: implications for common intracellular mechanisms involved in morphine tolerance. Pain 1995, 61:353-364.
8. Mercadante S. Malignant bone pain: physiopathology, assess-ment and treatment. Pain 1997, 69:1-18.
9. Luger N.M., Sabino M.A., Schwei M.J., Mach D.B., Pomonis J.D., Keyser C.P., Rathbun M., Clohisy D.R., Honore P., Yaksh T.L., Mantyh P.W. Efficacy of systemic morphine suggests a fundamental difference in the mechanisms that generate bone cancer vs. inflammatory pain. Pain 2002, 99:397-406.
10. Medhurst S.J., Walker K., Bowes M. A rat model of bone cancer pain. Pain 2002, 96:129-140.
11. Caraceni A., Weinstein S.M. Classification of cancer pain syndromes. Oncology 2001, 15:1627-1640.
12. Falah M., Schiff D., Burns T.M. Neuromuscular complications of cancer diagnosis and treatment. J. Support. Oncol. 2005, 3:271-282.
13. World Health Organization Cancer Pain Relief and Palliative Care 1990, World Health Organization, Geneva.
14. Jadad A.R., Browman G.P. The WHO analgesic ladder for cancer pain management. JAMA 1995, 274:1870-1873.
15. Hanks G.W., Expert Working Group of the Research Network of the EAPC. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br. J. Cancer 2001, 84:587-593.
16. Cherny N.J., Chang V., Frager G., Ingham J.M., Tiseo P.J., Popp B., Portenoy R.K., Foley K.M. Opioid pharma-cotherapy in the management of cancer pain. Cancer 1995, 76:1288-1293.
17. Portenoy R.K., Hagen N.A. Breakthrough pain: defini-tion, prevalence, and characteristics. Pain 1990, 41:273-281.
18. Mercadante S., Steering Committee of the European Associa-tion for Palliative Care (EAPC) Research Network. Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer 2002, 94:832-839.
19. Mercadante S. Opioid rotation in cancer pain: rationale and clinical aspects. Cancer 1999, 86:1856-1866.
20. Portenoy R.K., Rowe G. Adjuvant analgesic drugs. Cancer Pain: Assessment and Management 2003, 188-198. Cambridge University Press, Cambridge. E. Bruera, R.K. Portenoy (Eds.).
21. Mercadante S. Problems of long-term spinal opioid treatment in advanced cancer patients. Pain 1999, 79:1-13.
22. Mercadante S., Nicosia F. Celiac plexus block: a reap-praisal. Reg. Anesth. Pain Med. 1998, 23:37-48.